00:47 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting IL5Rα or CCR3 could help treat intestinal fibrosis caused by abdominal radiation therapy. In a mouse model of abdominal radiation-induced intestinal fibrosis, a mAb targeting IL5Rα, a tool compound CCR3...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 3 (CCR3; CD193)

Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting CCL7-CCR3 signaling could help treat prostate cancer. In patients with prostate cancer, tumor levels of CCR3 correlated with disease recurrence or metastasis after tumor...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

LeukoSite other research news

LKST and collaborators published in Science the identity of a chemokine receptor that targets Type 2 T helper cells to tissues involved in an allergic response. The migratory pattern of the different types of T...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly reduced allergen-induced LAR from baseline...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

ASM8: Completed Phase II enrollment

Pharmaxis completed enrollment of 16 adult asthmatics in a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial evaluating once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product:...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase II started

Pharmaxis began a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial in 16 adult asthmatics to evaluate once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product: ...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche's Genentech Inc.unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease.1 Nineteen of the 112 candidate cancer genes identified...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Topigen, NicOx, Pharmaxis deal

Pharmaxis will acquire Topigen in a stock deal valued at A$8.6 million (US$8 million) up front and A$13.5 million (US$12.6 million) in potential milestones, based on Pharmaxis' close of A$2.70 on Jan. 11, before the...
07:00 , Jun 25, 2009 |  BC Innovations  |  Targets & Mechanisms

Seeing CNV sooner

New research by a multinational team suggests that noninvasive imaging of CC chemokine receptor 3 could help detect wet age-related macular degeneration before retinal damage occurs.1 This would allow earlier therapeutic intervention, which is important...